Mucosat, 100 mg/ml 1 ml 10 pcs

The drug has chondroprotective, stimulating the regeneration of cartilage tissue, anti-inflammatory effect. Participates in the construction of the basic substance of cartilage and bone tissue, improves phosphorus-calcium metabolism in cartilage tissue, inhibits enzymes that disrupt the structure and function of articular cartilage, inhibits the process of degeneration of cartilage.

Stimulates the synthesis of proteoglycans, normalizes the metabolism of hyaline cartilage, promotes the regeneration of cartilage surfaces and articular bag. It prevents compression of the connective tissue, increases synovial fluid production and mobility of affected joints, reduces associated inflammation and pain, and helps reduce the need for NSAIDs. In degenerative changes of cartilage tissue it is a means of substitution therapy.

Positive effect is observed within 2-3 weeks after initiation of the drug. The therapeutic effect is retained for a long time (3-6 months) after the end of the course of treatment.

Pharmacokinetics:

Chondroitin sulfate sodium is easily absorbed after intramuscular injection. Within 30 minutes it is detected in the blood in significant concentrations: the maximum concentration is reached after 1 hour, then its content over 2 days gradually decreases.

Chondroitin sulfate sodium accumulates mainly in the cartilage.

The synovial membrane is not an obstacle to its penetration into the joint cavity. Within 15 minutes after intramuscular injection sodium chondroitin sulfate is found in synovial fluid, then it enters the articular cartilage where its content reaches a maximum after 48 hours.

Indications

Degenerative-dystrophic diseases of the joints and spine:

– osteoarthritis of the peripheral joints;

– intervertebral osteochondrosis and osteoarthritis.

To accelerate the formation of the bone callus in fractures.

Active ingredient

Composition

Active ingredient:

chondroitin sulfate sodium 100 mg

Excipients:

benzyl alcohol 9 mg;

water for injection up to 1 ml.

How to take, the dosage

Mucosat® is administered intramuscularly in 1 ml every other day. If tolerated well, the dose is increased to 2 ml starting with the fourth injection. The course of treatment is 25-30 injections. If necessary, repeated courses in 6 months are possible.

For the formation of the bone callus the course of treatment is 3-4 weeks (10-14 injections every other day).

Interaction

Contraindications

Hypersensitivity to the drug, susceptibility to bleeding, thrombophlebitis.

The use during pregnancy and lactation, as well as in children.

There are currently no data on the use of the drug Mucosat® during pregnancy and lactation period and in children.

Side effects

Similarities